These approaches address challenges like tumor heterogeneity and therapy resistance by combining TAM-targeted strategies (e.g., CSF-1R inhibition, PI3K pathway modulation) with immune checkpoint inhibitors or chemotherapy [52,82,290]. This evidence concerns the gene CSF1R and neoplasm.